Translational and Clinical Trial Correlates Core

转化和临床试验关联核心

• 批准号: 10526306
• 负责人: Claudia Marcela Diaz-Montero
• 金额: $ 45.44万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-14 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10526306
• 关键词: Bar Codes; Bioinformatics; Biological Assay; Biological Markers; Biometry; Cell Survival; Cells; Chairperson; Clinical; Clinical Research; Clinical Trials; Collaborations; Combined Modality Therapy; Computational Biology; Data; Data Analyses; Data Collection; Data Management Resources; Ensure; Flow Cytometry; Generations; Genes; Genomics; Health Sciences; Immunogenomics; Immunologic Monitoring; Immunologics; Immunology; Immunology procedure; Immunooncology; Immunophenotyping; Immunotherapy; Institutes; Laboratories; Molecular; Mutation; Pathologic; Pathology; Pathway Analysis; Pathway interactions; Performance; Peripheral Blood Mononuclear Cell; Plasma; Procedures; Process; Proteomics; Quality Control; Radiation; Reporting; Research Design; Research Personnel; Research Project Grants; Resources; Sampling; Sequence Analysis; Specimen; Standardization; Statistical Data Interpretation; T-Lymphocyte; T-cell receptor repertoire; Technology; Tissue Procurements; Treatment Efficacy; Tumor Tissue; Whole Blood; base; biobank; computing resources; data harmonization; data management; data resource; differential expression; human leukocyte antigen testing; interoperability; multidisciplinary; neoantigens; preclinical study; programs; radiation response; radiomics; response; screening; transcriptome; transcriptomics; translational clinical trial; translational goal; treatment response

PROJECT SUMMARY The goal of the Translational & Clinical Correlates Core (TCCC) is to provide the expertise and resources needed to conduct quality correlative analyses for the research projects and clinical studies proposed as part of our ROBIN Program. To accomplish this, we have assembled a multidisciplinary team with expertise in tissue procurement and biobanking, immune assays, immunogenomics, proteomics, radiomics, and state-of-the-art computational biology and biostatistics approaches. In Aim 1, the TCCC will provide highly standardized and validated procedures to procure, process and biobank specimens. This will ensure availability of well-catalogued and clinically annotated samples with optimal cell viability. In Aim 2, the TCCC will facilitate access to state-of- the-art platforms for the comprehensive molecular, pathologic, and immunologic profiling of collected biospecimens. This will provide a broad molecular assessment of the changes that occur in response to treatment and their contributions to response. In Aim 3, the TCCC will provide access to cutting-edge computational resources for the processing, analysis and interpretation of high-throughput data. Advanced bioinformatics will be provided by the Center for Immunotherapy and Precision Immuno-Oncology’s Computational Immunology Platform, and the Department of Quantitative Health Sciences (QHS) will assist with the statistical analyses. To facilitate harmonization of data management and analysis each participating institute will have a designated Data Resource Manager (Kattan for CC/Switchenko for Emory). This centralized approach will ensure optimal data collection, analysis, and sharing among projects and clinical studies.

项目总结